Emcure PharmaceuticalsNSE:EMCURE +2.18%41 EBITDA Margin % is 20.00% as of Mar. 2026, which is 1% above its 10-year median of 19.90. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review. Among 952 Drug Manufacturers companies, Emcure Pharmaceuticals ranks better than 67.75% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Emcure Pharmaceuticals EBITDA Margin % Related Terms
Emcure Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Emcure Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emcure Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Emcure Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emcure Pharmaceuticals (NSE:EMCURE) has a EBITDA Margin % of 20.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Emcure Pharmaceuticals and its competitors. This is near median its historical median of 19.90. Over the past decade, Emcure Pharmaceuticals' EBITDA Margin % has ranged from 18.84 to 25.95. According to the industry distribution chart, Emcure Pharmaceuticals ranks #307 out of 952 companies in the Drug Manufacturers industry, placing it in the top 32.2%.
Is Emcure Pharmaceuticals' EBITDA Margin % too high?
Emcure Pharmaceuticals' current EBITDA Margin % of 20.00% is near median its 10-year median of 19.90. Over the past 10 years, this metric has ranged from a low of 18.84 to a high of 25.95. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Emcure Pharmaceuticals' value of 20.00% is 60.4% above this industry median. Based on the distribution chart, Emcure Pharmaceuticals ranks #307 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Emcure Pharmaceuticals ranks #307 out of 952 companies for EBITDA Margin %. This puts Emcure Pharmaceuticals in the upper half of its industry. The industry median EBITDA Margin % is 12.47. Emcure Pharmaceuticals' value of 20.00% is 60.4% above this benchmark. Historically, Emcure Pharmaceuticals' own EBITDA Margin % has ranged from 18.84 to 25.95 over the past decade. While the company's 10-year median is 19.90 vs. the industry median of 12.47, Emcure Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emcure Pharmaceuticals's current EBITDA Margin % of 20.00% is 60.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Emcure Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emcure Pharmaceuticals's current EBITDA Margin % is 20.00%, which is near median its own 10-year median of 19.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current EBITDA Margin % of 20.00%. The current EBITDA Margin % is 20.00%, which is near median its 10-year median of 19.90 and 60.4% above the Drug Manufacturers industry median of 12.47. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current EBITDA Margin % is 20.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score
Get the complete analysis for NSE:EMCURE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:EMCURE has been successfully added to your 
